Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma.
Ryunosuke NakagawaKouji IzumiRen ToriumiShuhei AoyamaTaiki KamijimaHiroshi KanoTomoyuki MakinoRenato NaitoHiroaki IwamotoHiroshi YaegashiShohei KawaguchiKazuyoshi ShigeharaTakahiro NoharaAtsushi MizokamiPublished in: Japanese journal of clinical oncology (2024)
Biweekly administration of EV may be safer without compromising therapeutic efficacy than the standard schedule.
Keyphrases